Drug Trial Radar · NCT07459543
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
May 26, 2029
Study completion May 28, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
Conditions
- Unresectable Melanoma
- Metastatic Melanoma
Interventions
Nivolumab + RelatlimabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to 30 weeks
- Incidence of drug-related AEsTime frame: Up to 30 weeks
- Incidence of serious adverse events (SAEs)Time frame: Up to 30 weeks
- Incidence of drug-related SAEsTime frame: Up to 30 weeks
- Incidence of immune-mediated adverse events (IMAEs)Time frame: Up to 30 weeks
- AEs leading to discontinuation of treatmentTime frame: Up to 30 weeks
- Number of deathsTime frame: Up to 30 weeks
- Number of participants with laboratory abnormalitiesTime frame: Up to 30 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0011
Bhubaneswar, India
Local Institution - 0002
Chennai, India
Local Institution - 0006
Mumbai, India
Local Institution - 0005
Nagpur, India
Local Institution - 0004
New Delhi, India
Local Institution - 0001
New Delhi, India
Local Institution - 0012
Nashik, Dādra and Nagar Haveli and Damān and Diu, India
Local Institution - 0010
Mumbai, Maharashtra, India
Local Institution - 0009
Navi Mumbai, Maharashtra, India
Local Institution - 0008
Pune, Maharashtra, India
Local Institution - 0003
Bhubaneswar, Odisha, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.